Literature DB >> 12659664

Ribavirin in cancer immunotherapies: controlling nitric oxide augments cytotoxic lymphocyte function.

Richard E Kast1.   

Abstract

Either ribavirin (RBV) or cyclophosphamide (CY) can shift an immune response from Th2 toward a Th1 cytokine profile. CY is used in this role in various current cancer immunotherapy attempts but with mixed success. More potent and reliable immunoadjuvants and Th1 response biasing methods are needed. RBV is used today mainly to augment interferon-alpha treatment of hepatitis C. RBV shifts an immune response from Th2 toward Th1 more effectively than CY and may be a safe and useful adjuvant for current cancer immunotherapeutic efforts. RBV is thought to act by inhibition of tetrahydrobiopterin synthesis. Tetrahydrobiopterin is an essential cofactor for all known isoforms of nitric oxide synthase. Lowered nitric oxide favors Th1 development as high levels favor Th2 weighting.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12659664      PMCID： PMC1502126          DOI： 10.1016/s1476-5586(03)80011-8

Source DB:  PubMed          Journal:  Neoplasia        ISSN： 1476-5586            Impact factor:   5.715


  52 in total

Review 1.  Interferon-alpha as an immunotherapeutic protein.

Authors:  Diana L Brassard; Michael J Grace; Ronald W Bordens
Journal:  J Leukoc Biol       Date:  2002-04       Impact factor: 4.962

Review 2.  Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue.

Authors:  C D Mills
Journal:  Crit Rev Immunol       Date:  2001       Impact factor: 2.214

Review 3.  Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection.

Authors:  L Caradonna; M L Mastronardi; T Magrone; R Cozzolongo; R Cuppone; O G Manghisi; D Caccavo; N M Pellegrino; A Amoroso; E Jirillo; L Amati
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

4.  Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model.

Authors:  Pablo Matar; Viviana R Rozados; Silvia I Gervasoni; Graciela O Scharovsky
Journal:  Cancer Immunol Immunother       Date:  2001-11-16       Impact factor: 6.968

Review 5.  High-dose cyclophosphamide for aplastic anemia and autoimmunity.

Authors:  Robert A Brodsky
Journal:  Curr Opin Oncol       Date:  2002-03       Impact factor: 3.645

6.  Dominant role of intercellular adhesion molecule-1 in the pathogenesis of autoimmune diabetes in non-obese diabetic mice.

Authors:  S Martin; N K van den Engel; A Vinke; E Heidenthal; B Schulte; H Kolb
Journal:  J Autoimmun       Date:  2001-09       Impact factor: 7.094

7.  Reactions catalyzed by the heme domain of inducible nitric oxide synthase: evidence for the involvement of tetrahydrobiopterin in electron transfer.

Authors:  Amy R Hurshman; Michael A Marletta
Journal:  Biochemistry       Date:  2002-03-12       Impact factor: 3.162

8.  Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.

Authors:  J G McHutchison; J A Shad; S C Gordon; T R Morgan; M H Ling; J J Garaud; J K Albrecht; J L Dienstag
Journal:  J Viral Hepat       Date:  2001-11       Impact factor: 3.728

9.  Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.

Authors:  G D MacLean; M A Reddish; R R Koganty; B M Longenecker
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-01

10.  Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors.

Authors:  L D Fairbanks; M Bofill; K Ruckemann; H A Simmonds
Journal:  J Biol Chem       Date:  1995-12-15       Impact factor: 5.157
View more
  4 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.

Authors:  Richard E Kast; Nicolas Skuli; Samuel Cos; Georg Karpel-Massler; Yusuke Shiozawa; Ran Goshen; Marc-Eric Halatsch
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-07-11

3.  Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV.

Authors:  Anton A A Smith; Kaja Zuwala; Mille B L Kryger; Benjamin M Wohl; Carlos Guerrero-Sanchez; Martin Tolstrup; Almar Postma; Alexander N Zelikin
Journal:  Chem Sci       Date:  2014-09-16       Impact factor: 9.825

4.  Low-dose ribavirin treatments attenuate neuroinflammatory activation of BV-2 Cells by interfering with inducible nitric oxide synthase.

Authors:  Iva Bozic; Danijela Savic; Marija Jovanovic; Ivana Bjelobaba; Danijela Laketa; Nadezda Nedeljkovic; Mirjana Stojiljkovic; Sanja Pekovic; Irena Lavrnja
Journal:  Anal Cell Pathol (Amst)       Date:  2015-08-27       Impact factor: 2.916
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.